Clinical Investigation Center

Early detection to target hemangiosarcoma cells in dogs: The Shine On Project

submenu

Shine, a photo of a golden retrieverShine, the golden retriever for which this study is named

Current Status: Phase 1&2 Open and enrolling
Principal Investigator: Jaime Modiano, VMD, PhD
Contacts: Dr. Modiano: modiano@umn.edu
Amber Winter, Senior Research Study Technician, alwinter@umn.edu, 612-624-1352

What is the project?

"Early Detection to Target Hemangiosarcoma Cells in Dogs (Shine On)" was conceived to reduce the mortality and the suffering caused by canine hemangiosarcoma. The goal of this project is to develop effective methods for early detection and for prevention of canine hemangiosarcoma. We will use a blood test to look for the cells responsible for establishing and maintaining the disease, and then use an experimental drug treatment that attacks those same cells in order to prevent development of the tumor. Read more about the phases of the project, and how you can support it.

Phase 1&2 Samples Needed Now

Phase 1 is to collect blood samples for the hemangiosarcoma detection test. Phase 2 is to retest the same dogs in Phase 1 for further refinement of the hemangiosarcoma detection test. We need to collect a blood sample in the categories below, before surgery (Categories 1, 2, 3). We may not know which category a dog fits into until after surgery and diagnosis, but once we have the diagnosis, we will contact owners about the retest schedule. (For example, a dog scheduled for splenectomy may fit in Category 1 or Category 2). All dogs will be recruited from cases being seen at the Veterinary Medical Center.

Category-1. Dogs with confirmed hemangiosarcoma. Dogs can have a pathologically confirmed diagnosis of hemangiosarcoma from any body site, at any stage of disease, of any pathological grade, and dogs can be of any breed, age and sex. We will ask to retest dogs in this group every 60 days for one year.
Category-2. Dogs with confirmed non-neoplastic (non-cancerous) splenic lesions. This group includes dogs that have a pathologically confirmed diagnosis of splenic nodular hyperplasia and/or splenic hematoma and/or splenic hemangioma. The disease can be at any stage and dogs can be of any breed, age and sex. We will ask to retest dogs in this group every 6-months for up to two years.
Category-3. Dogs with any confirmed cancer other than hemangiosarcoma. This group includes dogs that have a pathologically confirmed diagnosis of cancer other than hemangiosarcoma, specifically malignant lymphoma (any subtype), osteosarcoma, soft tissue sarcoma, or carcinoma. The cancer can be in any anatomical site, at any stage, have any pathological grade, and dogs can be of any breed, age and sex. We will ask to retest dogs in this group every 6-months for up to two years.
Category-4. Healthy young dogs. We are looking for 25 dogs aged 2-4 years old with no evidence of any disease. Dogs will be recruited from our general practice well-health program and from the hospital staff pet population.

If you are interested in having your dog participate in this phase of the study, please contact Amber Winter (see above).